恆指午後曾漲近500點 申洲、舜宇及藥明生物漲7%-10% 惟宏橋續挫半成
雖然聯儲局主席鮑威爾重申將「無條件」抗擊通脹,但指標十年期美債息率昨晚回落至3.1厘之下。美股期貨全面續彈0.5%-0.8%,納指一百期貨續跑贏,曾漲1.2%至11,875,現報11,831,續彈0.8%;道指期貨曾漲223點高見30,895,現報30,819,續彈147點或0.5%。亞太股市全面造好,澳股、日經、菲股、韓股及港股升1%-2%。
恆指兩連升,午後在科指急漲4.4%至4,859及國指和工商指數升2.3%及3.2%推動,最多漲488點或2.3%高見21,762,現報21,720,急漲446點或2.1%,成交額1,213億元。
中央深改委日前通過《強化大型支付平台企業監管促進支付和金融科技規範健康發展工作方案》,中金指有助金融科技業有序整改。新經濟股全面上揚,尤其是阿里巴巴(09988.HK)午後高見115.5元,現報114.2元,續升5.7%。騰訊(00700.HK)、京東(09618.HK)、美團(03690.HK)及網易(09999.HK)續升逾2%-3.5%,分別高見386元、252.6元、200.2元及148.2元。
獲瑞信重申「跑贏大市」的藍籌舜宇(02382.HK)午後曾急漲9.8%高見119.6元,現報118.7元,續漲9.1%。
內需股潤啤(00291.HK)、蒙牛(02319.HK)、李寧(02331.HK)、安踏(02020.HK)及吉利(00175.HK)升逾2.5%-6.5%,後三者跑贏,分別高見68.1元、88元及18.44元,漲近5%-7%。此外,近期受困於美國經濟數據疲弱跑輸的出口股創科(00669.HK)及申洲(02313.HK)發力追落後,最高見85.45元及98.9元,現報85元及97.4元,升4.2%及6.8%,後者股價重越10天線(94.5元)。
中生製藥(01177.HK)、阿里健康(00241.HK)及藥明生物(02269.HK)升4.6%-10%,後者最強報77元,創逾四個月高。
金融股以平安(02318.HK)及港交所(00388.HK)表現較好,股價續升逾2%-4%,後者股價曾高見377元。
然而,宏橋(01378.HK)三連跌,最低見8.2元,創逾三個月低,現報8.4元,續挫5.1%。此外,內需股恆安(01044.HK)及內房龍湖(00960.HK)和中海外(00688.HK)反覆跌逾1%,後者股價三連吐。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.